Hybrid growth: Ranbaxy starts development of generics for Daiichi Sankyo in China
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories is expected to play a significant role in parent company Daiichi Sankyo's growth plans in the Chinese generics market, in addition to Japan, as both companies leverage opportunities from their hybrid business model.